The leading assignee in this dataset holds 375 of the 5,619 records in scope, more than double the fifth-place count of 172. The top five assignees combined account for 22.9% of all records, and the top ten account for 34.5%, which means concentration is real at the very top but the majority of filings still come from a long tail of smaller filers. Names include major structural heart and electrophysiology device makers alongside smaller specialist entrants.

Filings rose from 271 in 2017 to a peak of 500 in 2020, then declined to 306 by 2024, a 37% drop over that three-year span. The 2025 and 2026 figures in any dataset like this will look lower still, but that is a publication-lag artefact — patent applications typically take about 18 months to publish, so the most recent one to two years always understate true filing activity. The honest read is that volume has cooled from its 2020 peak, not that the field is closing.

US20060064062A1, assigned to St. Jude Medical’s Atrial Fibrillation Division and published in 2006, claims curved transseptal puncture needles and needle assemblies with specific tip bevel configurations — tangential back bevel, reverse tangential back bevel, and conical reverse bevel — oriented relative to the needle’s curvature. A new design should be checked against these specific bevel-and-curvature combinations rather than against transseptal puncture generally, since the claims are narrowly drawn to tip geometry. Designs using different tip geometries or non-curved needle bodies may sit outside its scope, but that requires a specific claim-by-claim comparison.